Halt Medical Announces CMS Assignment of Ambulatory Payment Classification for RF Ablation of Uterine Fibroids
LIVERMORE, Calif., Dec. 2, 2013 /PRNewswire/ — Halt Medical is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) has established a new Ambulatory Payment Classification (APC) for Radiofrequency (RF) Ablation of Uterine Fibroids. The APC 174 carries a reimbursement rate of $8,593.40 for the single-use handpiece and the hospital’s other operating costs related to the procedure. The physician reports services under the newly created CPT code – 0336T, and is reimbursed separately. The APC and CPT codes will become effective January 1, 2014.
“The assignment of an APC recognizes that RF ablation with the Acessa System is an important option for women suffering from uterine fibroids,” said Jayne A. Little, Halt Medical’s VP of Global Healthcare Economics. Jeffrey M. Cohen, CEO of Halt Medical added, “Today’s decision further validates the Acessa Procedure in the treatment algorithm of symptomatic uterine fibroids.” David J. Levine, MD has shared, “By recognizing this procedure and establishing a fee schedule, I’m able to continue to offer Acessa as a viable treatment option for my patients. They’re the real winners here.”
The Acessa Procedure is a minimally invasive laparoscopic procedure that delivers radiofrequency energy to destroy the fibroids. After treatment, the fibroid is re-absorbed by the surrounding tissue. Acessa allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities. The Acessa System is now available at leading medical centers throughout the U.S.
About Halt Medical, Inc.
Founded in 2004, Halt Medical is a medical device innovator focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com. To connect with Halt Medical on Facebook visit www.facebook.com/acessasystem or on Twitter at www.twitter.com/acessasystem.
SOURCE Halt Medical, Inc.